Arcutis Biotherapeutics, Inc.
Every calculator, already run for ARQT
Open the full toolkit →You have the numbers on ARQT. Get the argument.
A written report on which of these readings actually decide the outcome for Arcutis Biotherapeutics, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
7 analysts covering ARQTAnalyst Price Target Disagreement for Arcutis Biotherapeutics, Inc.
Wall Street's bull case implies +49% from the current price; the bear case implies +26%. Analysts are relatively aligned on ARQT's range.
Ownership & short interest
Insider Trading Activity for ARQT
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Arcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
ARQT — frequently asked
Is ARQT a buy right now?
Wall Street's consensus rating on Arcutis Biotherapeutics, Inc. is Buy across 7 analysts, with a mean price target of $37.00 (+37% vs. the current $26.92). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is ARQT overvalued?
ARQT trades at 122.4x trailing earnings, against a DCF fair value of $2 per share. The current price implies 40% annual free-cash-flow growth for a decade. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
When is ARQT's next earnings date?
Arcutis Biotherapeutics, Inc. is next scheduled to report earnings around Oct 27, 2026. A full ARQT research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Arcutis Biotherapeutics, Inc.?
Analysts covering Arcutis Biotherapeutics, Inc. (ARQT) range from a bear-case target of $34.00 to a bull-case high of $40.00, with a mean consensus target of $37.00 across 7 analysts. The spread of $6.00 (22% of the current price) indicates moderate disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Arcutis Biotherapeutics, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Arcutis Biotherapeutics, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full ARQT research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Arcutis Biotherapeutics, Inc., in minutes. 3 free reports included with every account — no credit card required.